US Pharma Tariff 2026: Decoding the 100% Patented Drug Levy and the Generic Exemption

Economy & Trade

The US administration under President Donald J. Trump has implemented a 100% tariff on patented pharma products to curb import dependence. While Indian generics are exempt for now, a one-year review and API onshoring rules signal long-term shifts.

Industries

India’s Race to Manufacture Affordable Obesity Drugs Amid Ozempic’s Market Entry

India’s obesity-drug market is transforming as semaglutide goes off patent, driving Ozempic's generic manufacturing, price shifts, and new opportunities in GLP-1 therapies.

Economy & Trade

US Tariff Twists: Where Does India Stand and How Will Exporters Get Impacted?

With the US Supreme Court tariff ruling, followed by new solar import duties of 125.87 percent on Indian exporters, India-US trade dynamics are being reshaped, prompting exporters and investors to reassess pricing strategies, supply chains, and tariff risk exposure.

Industries

New Drug Manufacturing Rules 2026: India's 3-Tier Change Classification & DCGI Licensing Overhaul

Navigate the 2026 drug manufacturing reforms: a guide to India's mandatory pharma change reporting, 3-tier risk classifications, and standardized Drugs Controller General of India (DCGI) licensing norms.

Get free access to our subscriptions and publications

Subscribe to receive weekly India Briefing news updates, our latest doing business publications, and access to our Asia archives.

Sign Up Now
India Briefing

Economy & Trade

Economy & Trade

US Pharma Tariff 2026: Decoding the 100% Patented Drug Levy and the Generic Exemption

Apr 03

The US administration under President Donald J. Trump has implemented a 100% tariff on patented pharma products to curb import dependence. While Indian generics are exempt for now, a one-year review and API onshoring rules signal long-term shifts.

 

Tax & Accounting

Tax & Accounting

Transitioning From Form 10F to Form 41: New DTAA Compliance Under Income-tax Act, 2025

Apr 01

DTAA relief in India now requires Form 41 under Section 159(8) of the Income-tax Act, 2025. Explore new documentation rules and tax residency certificate (TRC) mandates for non-residents.

 

Legal & Regulatory

Legal & Regulatory

Remote Work in India: Legal Framework, Employee Rights, and Compliance Guide for Employers

Apr 02

Navigate WFH and remote work compliance in India under the new 2026 Labor Codes. Learn about employer obligations for payroll, provident fund (PF), tax, and employee rights.

Industries

Industries

US Pharma Tariff 2026: Decoding the 100% Patented Drug Levy and the Generic Exemption

Apr 03

The US administration under President Donald J. Trump has implemented a 100% tariff on patented pharma products to curb import dependence. While Indian generics are exempt for now, a one-year review and API onshoring rules signal long-term shifts.

 

HR & Payroll

HR & Payroll

Remote Work in India: Legal Framework, Employee Rights, and Compliance Guide for Employers

Apr 02

Navigate WFH and remote work compliance in India under the new 2026 Labor Codes. Learn about employer obligations for payroll, provident fund (PF), tax, and employee rights.

 

Expert Guidance about Business in Asia

Dezan Shira & Associates is a pan-Asia, multi-disciplinary professional services firm, providing market entry, legal, accounting, tax, HR, technology and operational advisory to international investors.

Business Updates for All Asia Markets

Asia Briefing publishes articles, magazines, and guides on doing business in Asia. Dezan Shira & Associates has produced the publication since 1999.

About Asia Briefing Ask Us a Question

Need More Guidance?

India Briefing Publications

Download magazines and guides on doing business in India.

Download Now
Back to top